Literature DB >> 17881670

Clinical manifestations of the anti-phospholipid syndrome as defined by the updated Sapporo classification criteria.

Jesse Drijkoningen, Jan Damoiseaux, Pieter van Paassen, Jan Willem Cohen Tervaert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17881670      PMCID： PMC1994325          DOI： 10.1136/ard.2007.070680

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

Review 1.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

Authors:  W A Wilson; A E Gharavi; T Koike; M D Lockshin; D W Branch; J C Piette; R Brey; R Derksen; E N Harris; G R Hughes; D A Triplett; M A Khamashta
Journal:  Arthritis Rheum       Date:  1999-07

Review 2.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

3.  The antiphospholipid/cofactor syndrome: results of routine screening for antibodies to beta2-GPI upon suspicion of the antiphospholipid syndrome.

Authors:  Jgmc Damoiseaux; Mcef Wijffels; G M Willems; E M Bevers; M E A Spaanderman; E C M van Pampus; J W Cohen Tervaert
Journal:  Scand J Rheumatol       Date:  2004       Impact factor: 3.641

4.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

Review 5.  The concept and classification of antiphospholipid/cofactor syndromes.

Authors:  D Alarcón-Segovia; A R Cabral
Journal:  Lupus       Date:  1996-10       Impact factor: 2.911

6.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

Authors:  M Galli; P Comfurius; C Maassen; H C Hemker; M H de Baets; P J van Breda-Vriesman; T Barbui; R F Zwaal; E M Bevers
Journal:  Lancet       Date:  1990-06-30       Impact factor: 79.321

7.  Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.

Authors:  E Matsuura; Y Igarashi; M Fujimoto; K Ichikawa; T Koike
Journal:  Lancet       Date:  1990-07-21       Impact factor: 79.321

8.  Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Jean-Charles Piette; Josep Font; Munther A Khamashta; Yehuda Shoenfeld; María Teresa Camps; Soren Jacobsen; Gabriella Lakos; Angela Tincani; Irene Kontopoulou-Griva; Mauro Galeazzi; Pier Luigi Meroni; Ronald H W M Derksen; Philip G de Groot; Erika Gromnica-Ihle; Marta Baleva; Marta Mosca; Stefano Bombardieri; Frédéric Houssiau; Jean-Christophe Gris; Isabelle Quéré; Eric Hachulla; Carlos Vasconcelos; Beate Roch; Antonio Fernández-Nebro; Marie-Claire Boffa; Graham R V Hughes; Miguel Ingelmo
Journal:  Arthritis Rheum       Date:  2002-04

9.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

Authors:  H P McNeil; R J Simpson; C N Chesterman; S A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205
  9 in total
  2 in total

1.  Silicone implant incompatibility syndrome (SIIS): a frequent cause of ASIA (Shoenfeld's syndrome).

Authors:  J W Cohen Tervaert; R M Kappel
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 2.  Vitamin D deficiency as a risk factor for the development of autoantibodies in patients with ASIA and silicone breast implants: a cohort study and review of the literature.

Authors:  Maartje J L Colaris; Rene R van der Hulst; Jan Willem Cohen Tervaert
Journal:  Clin Rheumatol       Date:  2017-03-17       Impact factor: 2.980
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.